NEULAND LAB LTD. Fair Value
NEULANDLAB · Healthcare · Current price ₹23,035
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹1,662 | 21% ROE fading to 12% over ~3 yrs, on ₹1461 book |
| Relative P/E | ₹11,096 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹3,054 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹24,335 | Street consensus 12-month target price |
Is NEULAND LAB LTD. undervalued?
DocStoX estimates the fair value of NEULAND LAB LTD. at ₹8,087 per share, versus the current market price of ₹23,035. That puts the stock about -64.9% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹1,662), Relative P/E (₹11,096), Graham floor (₹3,054), Analyst target (₹24,335). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹1,662 (bear) to ₹8,087 (base) to ₹24,335 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on NEULAND LAB LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.